参考文献/References:
[1] Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by the EGR-receptor. Curr Opin Cell Biol, 1999, 11(2):190-196.
[2] Capdevila J, Elez E, Maearulla T, et al. Anti-epidermal growth factor receptor monoelonal antibodies in cancer treatment. Cancer Treat Rev, 2009, 35(4):354-363.
[3] Casanova ML, Larcher F, Casanova B, et al. A critical role for rasmediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res, 2002, 62(12):3402-3407.
[4] Sasaki T, Kitadai Y, Nakamura T, et al. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. Neopla-sia, 2007, 9(12):1066-1077.
[5] Galizia G, Lieto E, Ferraraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol, 2006,13(6):823-835.
[6] Varella-Garcia M, Diebold J, Eberhard DA, et al. EGFR fluorescence in situ hybridisation assay:guidelines tot application to nonsmall-cell lung cancer. J Clin Pathol, 2009, 62(11):970-977.
[7] Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX):an open-label randomised phase III trial. Lancet, 2009, 373(9674):1525-1531.
[8] Yarden Y, Sliwkowski MX. Untangling the ErbB signalling net-work, Nat Rev Mol Cell Biol, 2001, 2(2):127-137.
[9] Linardou H, Dahabreh IJ, Bafalonkos D, et al. Somatic EGFR muta-tions and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol, 2009, 6(6):352-366.
[10] Giaccone G, Johnson D, Seagliotti GV, et al. Results of a multivariate analysis of prognostic factors of overall survival of patients with advaneed non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large Phase III trials (INTACT 1 and 2). Proe Am Soe Clin Oneol, 2003, 22:627.
[11] Kanteti R, Yala S, Ferguson MK, et al. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxieol Oneol. 2009, 28(2):89-98.
[12] Fredriksson A, Johnström P, Thorell JO, et al. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci, 1999, 65(2):165-174.
[13] Rae JM, Lippman ME. Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. Breast Cancer Res Treat, 2004, 83(2):99-107.
[14] Wang H, Yu JM, Yang GR, et al. Further characterization of the epidermal growth factor receptor ligand 11C-PD153035, Chin Med J (Engl), 2007, 120(11):960-964.
[15] Cole GW Jr, Alleva AM, Reddy RM, et al. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg, 2005, 129(5):1010-1017.
[16] Pal A, Glekas A, Doubrovin M, et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol, 2006, 8(5):262-277.
[17] Cai W, Chen K, He L, et al. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody, Eur J Nucl Med Mol Imaging, 2007, 34(6):850-858.
[18] Abourbeh G, Dissoki S, Jacobsou O, et al. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol, 2007, 34(1):55-70.
[19] Fredriksson A, Stone-Elander S. PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo. Methods Mol Med, 2003, 85:279-294.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[3]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[4]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[5]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[6]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[7]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[8]程维维,王辉.促甲状腺激素受体与甲状腺癌关系的研究进展[J].国际放射医学核医学杂志,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
CHENG Wei-wei,WANG Hui.Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
[9]黄丽娟,陈宁,叶静,等.反义肽核酸对促甲状腺激素受体mRNA表达的影响[J].国际放射医学核医学杂志,2012,36(5):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
HUANG Li-juan,CHEN Ning,YE Jing,et al.The effects of antisense peptide nucleic acid on the expression of thyroid stimulating hormone receptor mRNA[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
[10]刘淼,刘兴党.生长抑素受体显像剂99Tcm-奥曲肽的SPECT研究[J].国际放射医学核医学杂志,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
LIU Miao,LIU Xing-dang.Development of study on SPECT imaging with radioisotope 99Tcm-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
[11]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[12]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[13]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[14]柳杰,刘佩芳.乳腺癌X射线征象与雌激素受体、孕激素受体和C-erbB-2表达相关性的研究进展[J].国际放射医学核医学杂志,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
LIU Jie LIU,Pei-fang.Development of the correlation study between mammographic appearances and expression of estrogen receptor, progesterone receptor and C-erbB-2 in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
[15]汪永红,陈文新,何品玉.肿瘤表皮生长因子受体的分子显像研究[J].国际放射医学核医学杂志,2009,33(4):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
WANG Yong-hong,CHEN Wen-xin,HE Pin-yu.Tumor epidermal growth factor receptor molecular imaging research[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(5):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
[16]黄顺,韩彦江,郑希,等.靶向表皮生长因子受体小分子类PET显像剂研究进展[J].国际放射医学核医学杂志,2017,41(1):50.[doi:10.3760/cma.j.issn.1673-4114.2017.01.010]
Huang Shun,Han Yanjiang,Zheng Xi,et al.PET imaging agents of small molecules inhibitors targeting EGFR[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(5):50.[doi:10.3760/cma.j.issn.1673-4114.2017.01.010]
[17]郑玉民,王自正,王峰,等.以表皮生长因子受体为靶点的肿瘤分子靶向治疗[J].国际放射医学核医学杂志,2007,31(1):21.
ZHENG Yu-min,WANG Zi-zheng,WANG Feng,et al.Epidermal growth factor receptor targeted molecularly therapies of cancers[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(5):21.
[18]袁卫红,罗志航,彭荣宗,等.肺癌与表皮生长因子及其受体关系的研究[J].国际放射医学核医学杂志,2006,30(5):261.
YUAN Wei-hong,LUO Zhi-hang,PENG Rong-zong,et al.The study on the correlation between EGF, EGFR and lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):261.
[19]何蕊,朱高红.甲状腺髓样癌靶向治疗的研究进展[J].国际放射医学核医学杂志,2018,(2):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]
He Rui,Zhu Gaohong.Research status of medullary thyroid carcinoma targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]